Vivaglobin Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The vivaglobin market research report is one of a series of new reports that provides vivaglobin market statistics, including the vivaglobin industry global market size, regional shares, competitors with the vivaglobin market share, detailed vivaglobin market segments, market trends, and opportunities, and any further data you may need to thrive in the vivaglobin industry. This vivaglobin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the increasing prevalence of autoimmune disorders, increasing clinical trials, increasing investment in research and development, increasing obesity, and increasing autoimmune disorders. Major trends in the forecast period include personalized medicine, facility expansion, increasing investment in research and development, strategic collaboration, and technological advancement.

The growing prevalence of primary immunodeficiency diseases (PI) is expected to significantly contribute to the expansion of the Vivaglobin market in the coming years. Primary immunodeficiency diseases are a group of conditions where the immune system is either absent or insufficient, making it difficult for the body to fight off infections and leaving patients more vulnerable to illness. The increasing number of cases is attributed to advancements in diagnostic technologies, better awareness of these diseases, improved genetic testing, and the identification of cases that were previously undiagnosed. Vivaglobin helps manage these conditions by providing a reliable supply of antibodies through subcutaneous administration, which boosts the immune system's ability to fight infections and reduces the frequency and severity of recurrent illnesses in patients. For example, a report by Thermo Fisher in August 2023 estimated that approximately 6 million people worldwide suffer from primary immunodeficiency, with around 5,000 cases in the UK alone. This growing prevalence is expected to drive demand for Vivaglobin.

The growing investment in research and development (R&D) is expected to accelerate the growth of the Vivaglobin market. R&D in the medical field focuses on the development of new treatments, drugs, and medical technologies, including clinical trials and laboratory studies, all aimed at improving healthcare outcomes. Increased investment in R&D fosters the discovery of innovative therapies, enhances patient outcomes, and addresses emerging health challenges. This trend benefits Vivaglobin by supporting innovations in immunoglobulin formulations, refining administration methods, and improving both the accessibility and effectiveness of treatments for patients with primary immunodeficiency diseases. According to the Department of Health and Social Care in the UK, pharmaceutical research and development expenditure reached approximately $11.1 billion in 2022, accounting for 18% of total business R&D spending in the UK that year. This investment underscores the growing importance of R&D in the pharmaceutical industry and its positive impact on the Vivaglobin market.

The expanding geriatric population is also expected to drive the growth of the Vivaglobin market. This population typically consists of adults aged 65 and older, who often face specific health, social, and economic challenges. The rise in the geriatric population is largely due to improvements in healthcare, which have led to increased life expectancy, alongside lower birth rates. Vivaglobin helps support older adults by offering an effective and convenient subcutaneous immunoglobulin therapy that strengthens the immune system. This therapy reduces the risk of infections and enhances the overall quality of life for elderly individuals who may have weakened immunity or primary immunodeficiency diseases. According to the Administration for Community Living, 17.3% of the population in the U.S. was aged 65 or older in 2022, a figure expected to grow to 22% by 2040. The increase in the aging population is a key factor that will continue to drive the demand for Vivaglobin.

The key company operating in the vivaglobin market is CSL Behring GmbH

North America was the largest region in the vivaglobin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vivaglobin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vivaglobin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Vivaglobin is a subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiency (PI), a group of disorders that impair the immune system's ability to combat infections. It provides a continuous supply of antibodies to help enhance the immune system and protect against recurrent infections.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Vivaglobin include primary immune deficiency (PID), secondary immune deficiency (SID), chronic inflammatory demyelinating polyneuropathy (CIDP), and other related conditions. Primary immune deficiency (PID) encompasses a group of genetic disorders that weaken the immune system, making it harder for the body to fight infections. Vivaglobin is distributed through various channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by a wide range of patients, including adults, geriatrics, and pediatric patients.

The vivaglobin market consists of sales of intravenous immunoglobulin (IVIG) products, subcutaneous immunoglobulin (SCIG) formulations, and hyperimmune globulin therapies. This market also encompasses associated costs for distribution, healthcare professional services, and patient support programs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.